Abstract: The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals.

Abstract: The present invention relates to a formulation of Spinacea oleracea useful for the prevention or treatment of osteo-health related disorders. The present invention relates to the field of pharmaceutical formulation that provides extract, fractions, pure compound isolated from natural sources and formulation thereof useful for the prevention and treatment of various medical indications. Further, this invention relates to conditions associated with estrogen dependent or independent diseases (primary/secondary osteoporosis) or syndromes or disorders preferably relating to cartilage such as osteoarthritis caused in humans and animals. Furthermore, this invention relates to achievement of peak bone mass during skeletal growth and health in humans and animals.

Abstract: The present invention relates to a formulation of Spinacea oleracea useful for the prevention or treatment of osteo-health related disorders. The present invention relates to the field of pharmaceutical formulation that provides extract, fractions, pure compound isolated from natural sources and formulation thereof useful for the prevention and treatment of various medical indications. Further, this invention relates to conditions associated with estrogen dependent or independent diseases (primary/secondary osteoporosis) or syndromes or disorders preferably relating to cartilage such as osteoarthritis caused in humans and animals. Furthermore, this invention relates to achievement of peak bone mass during skeletal growth and health in humans and animals.

Abstract: The present invention relates to ulmoside A as a novel small molecule adiponectin receptor agonist useful for prevention or cure of metabolic diseases. The present invention further relates to the use of ulmoside-A (ULMA) ((2S,3S)-(+)-3?,4?,5,7-tetrahydroxydihydroflavonol-6-C-?-D-glucopyranoside) for alleviation, management or prevention or treatment of steroid-induced metabolic disorder. The present invention further relates to a pharmaceutical composition useful for prevention and/or treatment of various medical indications associated with metabolic diseases caused in humans and animals.

Abstract: Flavonol compounds, pharmaceutical compositions of the compounds and methods for treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.

Abstract: The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals.

Abstract: The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of general formula 2, K058: R1?R2?OH K012: R1?R2?OH, 2,3 double bond K068: R1?R2?H KIOOi R1?OH, R2?H mula 2 Wherein the marker compounds K012, K058, K068, K1OO ranges 6.7-12%, 1.7-4.5%, 0.6-1.2%, 1.7-4.5% respectively in alcoholic extract and a process of extraction thereof. According to another aspect of the invention provides a pharmaceutical composition comprising the said compound. The present invention further provides a method of treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.

Abstract: The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of general formula 2, K058: R1?R2?0H K012: R1?R2?OH, 2,3 double bond K068: R1?R2?H KIOOi R1?OH, R2?H mula 2 Wherein the marker compounds K012, K058, K068, K100 ranges 6.7-12%, 1.7-4.5%, 0.6-1.2%, 1.7-4.5% respectively in alcoholic extract and a process of extraction thereof. According to another aspect of the invention provides a pharmaceutical composition comprising the said compound. The present invention further provides a method of treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.

Abstract: Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti-osteoporosis (bone forming) activity of Butea species. It was thought to study the anti-osteoporotic activity of this plant. Thus, the present invention provides a pharmaceutical composition from the extracts of Butea monosperma for prevention or treatment of bone disorders, process of preparation and use thereof.

Abstract: The present invention relates to a process of isolation of bioactive eupalitin (3-O-O-D-galactopyranoside) of formula 1 possessing anti-osteoporosis activity by extraction of powdered leaves of Boerhaavia diffusa, with better yield:

Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.

Abstract: The present invention relates to a novel compound 8-(C-&bgr;-D-glucopyranosyl)-7,3′,4′-trihydroxyflavone, isolated from Pterocarpus marsupium useful in the treatment of diabetes. The present invention also relates to a method for the preparation of the compound and to the uses thereof.

Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.

Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.

Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.

Abstract: The present invention relates to a novel compound 8-(C-&bgr;-D-glucopyranosyl)-7,3′,4′-trihydroxyflavone, isolated from Pterocarpus marsupium useful in the treatment of diabetes. The present invention also relates to a method for the preparation of the compound and to the uses thereof.

Abstract: The present invention relates to a process of isolation of bioactive eupalitin (3-O-&bgr;-D-galactopyranoside) of formula 1 possessing anti-osteoporosis activity by extraction of powdered leaves of Boerhavia diffusa, with better yield 1

Abstract: A novel glucopyranoside, 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H) benzofuran-7-C-&bgr;-D-glucopyranoside of the formula 1 isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a pharmaceutical composition containing 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)benzofuran-7-C-&bgr;-D-glucopyranoside and to method for the treatment of diabetes using said compound.

Abstract: A novel glucopyranoside, 6-hydroxy-2-p-hydroxybenzylbenzofuran-7-C-&bgr;-D-glucopyranoside of the formula 1 isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a pharmaceutical composition containing 6-hydroxy-2-p-hydroxybenzylbenzofuran-7-C-&bgr;-D-glucopyranoside and to method for the treatment of diabetes using said compound.

Abstract: Pharmaceutical composition and a method useful for treating immunodeficiency in animals or human beings, said composition comprising effective amount of the extract obtained from any part of plant Cryptolepis buchanani, either as such or its individual constituents singly or in composition with each other, optionally associated with pharmaceutically acceptable additives.